BXRX - FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors

2023-09-28 08:43:07 ET

(24/7 MARKET NEWS) – Baudax Bio, Inc. (NASDAQ: BXRX) stated, this morning, that U.S. Food and Drug Administration (FDA) granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.

Baudax Bio is trading at $0.46, up $0.16 (+52.00%), on 219.19K premarket shares traded.

Its 52-week range is $0.30 to $12.24. It just crossed a key inflection point and its next key inflection point is 59-cents. If it breaks through that, on strong trading volume, it looks like it has several manageable waves to retrace to as high as $1, but the …

The post FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors appeared first on 24/7 Market News .

For further details see: